We reported previously that IL-15 plays a critical role in protecting effector CD8 ϩ T cells from apoptosis during the contraction phase following acute infection with Listeria monocytogenes by inducing antiapoptotic molecules. In the present study, we examined the effects of in vivo administration of rIL-15 on contraction of CD8 ϩ T cells after chronic infection with Mycobacterium bovis BCG and on the efficacy of BCG vaccination against Mycobacterium tuberculosis infection. Antigen-specific CD8 ϩ T cells reached an expansion peak at approximately Day 21, followed by a contraction after inoculation with rBCG expressing OVA. In vivo administration of rIL-15 from Days 22 to 42 after BCG inoculation inhibited apoptosis of effector CD8 ϩ T cells by up-regulating their Bcl-2 expression, resulting in a significant increase of antigen-specific memory CD8 ϩ T cells producing IFN-␥. However, the IL-15 treatment did not elicit improved efficacy of BCG vaccination against M. tuberculosis. These results suggest that IL-15 plays a critical role in protecting activated CD8 ϩ T cells from apoptosis during the contraction phase following BCG inoculation, although IL-15 administration alone at the contraction phase might not be sufficient to protect the efficient memory T cell responses against subsequent infection with M. tuberculosis. J. Leukoc. Biol. 86: 000 -000; 2009.
Introduction
TB has been a major worldwide cause of death for centuries. One-third of the world's population is infected with Mycobacterium tuberculosis, which causes 2 million deaths per year [1] . Mycobacterium bovis BCG vaccine confers incomplete protection against TB in adults, although it can protect children efficiently against the early manifestations of TB [2, 3] . This is partly because the BCG vaccine is not effective for inducing long-term cellular immunity mediated by antigen-specific memory CD4
ϩ and CD8 ϩ T cells. The size of the memory T cell pool is at least partly dependent on the amount of surviving T cells from T cell contraction by apoptosis after primary TCR-mediated activation. Several studies have shown that death of the majority of activated CD8 ϩ T cells responding to a foreign antigen in vivo can be prevented by the Bcl-2 family [4, 5] , which is known to be induced via signaling from the c␥-chain [5, 6] . Thus, c␥ cytokine family members may play a critical role in the survival of effector CD8 ϩ T cells, resulting in increased size of memory CD8 ϩ T cells, and may be useful in increasing the efficacy of BCG vaccine for TB. IL-15 is a member of the common ␥-chain cytokine family, which uses ␤-and ␥-chains of IL-2R for signal transduction and acts as a growth factor for memory CD8 ϩ T cells [7] . We found previously that IL-15 Tg mice, expressing IL-15 cDNA, encoding a secretable isoform, had an increased number of memory CD8 ϩ T cells in a naïve state and showed enhanced protection against infection with M. bovis BCG accompanied by an increase of antigen-specific CD8 ϩ T cells [8 -10] . On the other hand, we and others [11, 12] have reported that IL-15 Ϫ/Ϫ mice showed an impaired protective immunity to BCG or M. tuberculosis infection associated with a dramatic reduction in the numbers and function of CD8 ϩ T cells, although there was a conflicting report about protection against M. tuberculosis in IL-15 Ϫ/Ϫ mice [13] .
Thus, IL-15 may play important roles in the generation and maintenance of immunological memory mediated by memory CD8 ϩ T cells against mycobacterial infection.
We have reported recently that treatment of IL-15 only at the contraction phase was able not only to protect effector CD8 ϩ T cells from apoptosis during the contraction phase but also to increase the memory CD8 ϩ T cell pool following Listeria monocytogenes infection [14] . In the present study, we examined the effects of in vivo administration of rIL-15 on contrac-tion of CD8 ϩ T cells after inoculation with M. bovis BCG and on the efficacy of BCG vaccination against M. tuberculosis infection. In vivo administration of rIL-15 from Days 22 to 42 after BCG inoculation inhibited the contraction of effector CD8 ϩ T cells, resulting in a significant increase in the number of antigen-specific memory CD8 ϩ T cells producing IFN-␥. However, the treatment of rIL-15 did not provide efficient memory T cell responses against subsequent infection with M. tuberculosis.
MATERIALS AND METHODS

Mice
C57BL/6 mice, used at 6 -8 weeks of age, were obtained from Charles River Laboratories (Japan). Mice were maintained under specific pathogenfree conditions and offered food and water ad libitum. All experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences [15] .
Microorganisms rBCG-OVA were described previously [16, 17] . Briefly, BCG (Pasteur strain) was grown on Middlebrook 7H10 solid medium (Difco, Detroit, MI, USA). A partial sequence of the OVA gene 230-359, which encodes the SIINFEKL epitope and its flanking sequences, was cloned in the pMV261 vector, downstream of the Ag85B secretion signal and under the control of the heat shock protein 60 promoter. rBCG-OVA were dissolved in 7H9 medium (Difco) supplemented with oleic acid-albumin-dextrose-catalase enrichment (Difco). Small aliquots of rBCG-OVA suspended in 7H9 medium containing 10% glycerol were stored at -80°C until use. M. tuberculosis H37Rv were cultured and stored by the same method with rBCG-OVA. The concentration of bacteria was quantified by plate-counting. Before use, the bacteria were washed twice with PBS containing 0.05% Tween 80 and resuspended in PBS.
Bacterial infection and rIL-15 treatment
Naïve mice were i.p.-inoculated with 5 ϫ 10 6 CFU rBCG-OVA in a volume of 200 l PBS. From Day 22 after preimmunization, mice were i.v.-treated with rIL-15 (Takeda Chemical, Osaka, Japan; 0.5 g/day) or PBS every day until Day 42, and on Day 91 after preimmunization (49 days after the end of rIL-15 treatment), mice were treated with isoniazid (0.1 g/L) in drinking water for 4 weeks to clear the live BCG and then on Day 127, were i.t.-infected with 2 ϫ 10 5 CFU M. tuberculosis H37Rv in a volume of 50 l PBS under the Biohazard Level-3 procedures.
Antibodies and reagents
FITC-conjugated anti-CD3 (145-2C11), CD62L (MEL-14), CD127 (A7R34), IFN-␥ (XMG1.2); PE-conjugated anti-CD8␣ (53-6.7); PerCP-Cy5.5-labeled anti-CD4 (RM4-5) and CD8␣ (53-6.7); and allophycocyanin-conjugated anti-CD44 (IM7) and CD62L (MEL-14) mAb were purchased from BD PharMingen (San Diego, CA, USA). FITC-conjugated hamster anti-mouse activated form of Caspase-3 (C92-605), Bcl-2 mAb (3F11), and hamster anti-mouse isotype control were obtained from BD PharMingen. Annexin-V FITC apoptosis detection kit was purchased from Sigma-Aldrich (St. Louis, MO, USA). PE-conjugated OVA 257-264 H-2K b tetramers were purchased from MBL (Nagoya, Japan).
Cell preparation
PECs were obtained by lavage of the peritoneal cavity with 5 ml HBSS. PECs and splenocytes were prepared by centrifugation and resuspended in RPMI 1640 containing 10% FBS, 100 U/ml penicillin, 100 l/ml streptomycin, and 10 mM HEPES. Lung MNCs were prepared as described previously [18] . Briefly, lung tissue was minced and incubated with stirring at 37°C for 30 min in HBSS with 1.3 mM EDTA, followed by treatment at 37°C for 1.5 h with collagenase (150 U/ml, Invitrogen Life Technologies, Carlsbad, CA, USA) in RPMI 1640 with 10% FBS. The resulting suspension was pelleted by centrifugation, resuspended in 45% Percoll (Pharmacia, Uppsala, Sweden), layered on 66.6% Percoll, and centrifuged at 600 g. Cells at the gradient interface were harvested and washed extensively before use.
Flow cytometric analysis
Splenocytes, PECs, or lung MNCs were preincubated with a culture supernatant from 2.4 G 2 to prevent nonspecific staining. After washing, cells were stained with various combinations of mAb. The stained cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). The data were analyzed with CellQuest software (BD Biosciences).
Intracellular staining for cytokine, Bcl-2, or Caspase-3
Splenocytes and lung MNCs were harvested, washed, and incubated without any stimulation or with 5 g/ml PPD (Japan BCG Association, Tokyo, Japan) and 100 pg/ml rIL-2 (Takeda Chemical) for 6 h at 37°C and 5% CO 2 , with 10 g/ml brefeldin A (Sigma-Aldrich) added in the last 2 h or with 5 g/ml OVA 257-264 peptide for 4 h in the presence of brefeldin A at a concentration of 5 ϫ 10 6 in RPMI containing 10% FCS. After culture, cells were preincubated with 2.4 G 2 and stained with various combinations of mAb. After surface staining, cells were subjected to intracellular cytokine staining using a Fast Immune Cytokine System (BD Biosciences), according to the manufacturer's instructions. Briefly, cells were washed and fixed in 1000 l FACS lysing solution (BD Biosciences) for 10 min at room temperature and were then washed again, resuspended in 500 l FACS permeabilizing solution (BD Biosciences), and incubated for 10 min at room temperature. After washing, the cells were stained with FITC-conjugated IFN-␥ mAb or isotype control rat IgG (BD PharMingen).
Before staining for intracellular Bcl-2, splenocytes were stained for surface markers in FACS buffer with PerCP-Cy5.5-conjugated anti-CD8 mAb and PE-conjugated OVA 257-264 H-2K b tetramers for 60 min at 4°C and then were fixed, permeabilized, and stained with FITC-conjugated hamster antimouse Bcl-2 or its isotype control. For the staining of activated Caspase-3, cells were first cultured in 48-well flat-bottom plates without any stimulation for 24 h at 37°C and 5% CO 2 and then were stained for surface markers. Then, the cells were washed, fixed, and permeabilized using the Cytofix/ Cytoperm intracellular staining kit (BD Biosciences) and were finally incubated with anti-Caspase-3 at a 1/100 dilution in perm/wash buffer for 30 min at room temperature. After intracellular staining, fluorescence of the cells was analyzed by a FACSCalibur flow cytometer (BD Biosciences).
Annexin-V staining
Splenocytes from mice were stained for surface markers, and the amount of apoptosis was determined by staining these cells with Annexin-V FITC , according to the manufacturer's instructions. Briefly, cells were suspended in 1ϫ binding buffer at 500 l/tube and incubated with 5 l/tube Annexin-V FITC for 10 min in the dark at room temperature. Cells were washed twice with 1ϫ binding buffer to remove any unbound mAb. Samples were analyzed within 30 min.
Statistical analysis
The statistical significance of the data was determined by the Student's t-test; a value of P Ͻ 0.05 was considered significant.
RESULTS
Expansion and contraction of OVA 257-264 -specific CD8
؉ T cells in C57BL/6 mice after inoculation with rBCG-OVA Figure 3 , A and B, the number of PPD-specific IFN-␥-producing-CD8 ϩ T cells in the spleen from rIL-15-treated mice was significantly more than those in PBS-treated mice on Day 90 after inocuation (PϽ0.05), and the percentage of PPD-specific IFN-␥-producing-CD4 ϩ Th cells in the spleen was much the same in rIL-15-treated mice as in PBS-treated mice. Detectable levels of IFN-␥ ϩ cells could not be observed in the lung of rIL-15-and PBS-treated groups (Fig. 3A) . We next stimulated the cells from the spleen, PEC, or lung with OVA 257-264 peptide for cytokine FACS. There were significantly more OVA 257-264 -specific IFN-␥-producing-CD8 ϩ T cells in the spleen and lung from rIL-15-treated mice than from PBS-treated mice on Day 43 or Day 90 (Figs. 1B and 3, C and D, PϽ0.05) . Thus, rIL-15 treatment during the contraction phase resulted in a significant increase in the number of CD8 ϩ T cells producing IFN-␥ in lymphoid and nonlymphoid organs.
Impaired apoptosis in OVA 257-264 -specific CD8
؉ T cells in rIL-15-treated mice
To determine the apoptotic potential of OVA-specific CD8 ϩ T cells in the spleen from IL-15-treated mice on Day 90 after rBCG-OVA inoculation, we examined the expression level of Annexin-V, an early marker of apoptotic cells, or active Caspase-3, a terminal effector for apoptosis, in the OVA 257-264 -tetramer ϩ CD8 ϩ T cells. The expression level of both of these apoptotic markers was significantly lower in rIL-15-treated mice than in control mice (Fig. 3E, PϽ0.05) . The intracellular expression levels of the antiapoptotic protein Bcl-2 in the OVA-specific CD8 ϩ T cells from rIL-15-treated mice were significantly higher compared with those in PBS-treated mice (Fig. 3E, PϽ0.05) . Thus, in vivo administration of rIL-15 during the contraction phase after BCG infection prevented significantly more antigenspecific CD8 ϩ T cells from undergoing apoptosis. (Fig. 4A) . The PPD-specific IFN-␥-producing CD8 ϩ or CD4 ϩ T cells in the lung were examined on Day 28 or Day 70 after the challenge with M. tuberculosis. As shown in Figure 4B , the larger numbers of CD8 ϩ T cells in the lungs from rIL-15-treated mice produced IFN-␥ in response to PPD compared ϩ T cells in nonimmunized mice was sometimes higher than immunized mice, which may be a result of the 10 times higher bacterial burden in the organs (Fig. 5) . These data indicate that memory CD8 ϩ but not CD4 ϩ T cells from rIL-15-treated mice re-expanded to greater levels than those from PBS-treated mice after challenge with M. tuberculosis.
Effect of rIL-15 administration during the contraction phase on the efficacy of BCG vaccination against M. tuberculosis infection
The bacterial burden in rIL-15-or PBS-treated mice was determined on Day 28 or Day 70 after challenge with M. tuberculosis. As shown in Figure 5 , A and B, the bacterial numbers in lungs and spleens were significantly lower in rIL-15-treated or PBStreated mice than in nonimmunized mice (PϽ0.05). However, there was no significant difference between rIL-15-treated mice and PBS-treated mice in these organs. We also examined the histopathologic changes in the lungs of rBCG-OVA-immunized rIL-15-treated; rBCG-OVA-immunized PBS-treated; or nonimmunized 
CD8
ϩ T cells stained negative for anti-Annexin-V antibody or positive for antiactive Caspase-3 antibody, and for Bcl-2 expression, the numbers showed the mean fluorescence intensity of OVA-tet
. Data of a representative are shown from three separate experiments and are expressed as means Ϯ sd of three mice of each group. *, P Ͻ 0.05. mice on Day 70 after M. tuberculosis challenge. In nonimmunized mice, little lymphoid infiltration was found, and the whole pulmonary lobe was filled with lowly structured, loose granulomas. In rBCG-OVA-immunized IL-15-and PBS-treated mice, a great deal of lymphoid follicle formations was found, but there was no significant difference between these two groups (Fig. 6) .
DISCUSSION
It has been reported that treatment of members of the common ␥-chain cytokine family, including IL-2, IL-7, or IL-15 from the beginning of immunization or infection, did not affect the effector/memory CD8 ϩ T cell population quanti-and qualitatively, resulting in no efficacy on treatment of infectious diseases [13, 19] . We here show that in vivo administration of rIL-15 from Days 22 to 42 after BCG inoculation inhibited the contraction of effector CD8
ϩ T cells, resulting in a significant increase of antigen-specific memory CD8 ϩ T cells. However, the IL-15 treatment, only at the contraction phase after BCG vaccination, failed to elicit improved efficacy of vaccination against M. tuberculosis as compared with BCG alone, presumably as the higher level of memory CD8
ϩ T cells did not last for a long time.
Unlike acute infection with L. monocytogenes, priming of CD8 ϩ T cells during infection of mice with M. bovis BCG was delayed, weaker in magnitude, which peaked at approximately the 3rd week after infection, and subsequently, declined to a low level [20] . During acute infection with L. monocytogenes, antigen-specific CD8 ϩ T cells differentiate rapidly into effectors (CD62L low CD44 high ), most of which subsequently die by apoptosis during the contraction phase, and CD8 ϩ T cells primed during chronic BCG infection differentiated primarily into the central memory phenotype (CD62L high CD44 high ) that correlated with subsequent reduced attrition of the primed cells [17] . It has been found recently that thymic emigrants masked the contraction phase of the CD8 ϩ T cell response in the mouse model of chronic lymphocytic choriomeningitis virus infection [21] . Therefore, CD8 ϩ T cell contraction may be more obscure during chronic infection with BCG than during acute infection with L. monocytogenes infection. However, we found in the present study that although priming of CD8 ϩ T cells of mice during BCG infection was delayed and weaker in magnitude, peaking at approximately the 3rd week of infection, the CD8 ϩ T cells declined to a low level subsequently by Day 42 after BCG infection. Furthermore, in vivo administra- ). Recently, it has been reported that CD8 ϩ T contraction in acute infection involved only Bim, a preapoptic Bcl-2 homology 3-only protein, with no contribution by Fas, whereas both pathways were involved in CD8 ϩ T cell contraction in chronic infection [22] . Thus, the potency of IL-15 at the contraction phase may influence the fate of CD8 ϩ T cells in a different way between acute and chronic infection. ϩ T cells play a requisite role in this protection [23, 24] . Several vaccination strategies can be settled to induce protective memory CD8 ϩ T cells. We have reported recently that vaccination of bone marrow-derived dendritic cell pulsed with H2-M3 binding peptide TB2 [25] ϩ T cells, leading to protection against i.t. infection with M. tuberculosis infection [27] . We reported previously that BCG immunization in IL-15 Tg mice showed an increase of antigen-specific CD8 ϩ T cells and elicited improved protection against M. tuberculosis [10] . Furthermore, we have reported that rBCG-Ag85B-IL15 induced stronger responses by antigen-specific CD8 ϩ T cells and robust protection in lung against i.t. challenge of M. tuberculosis [28] . In the present study, we show that in vivo administration of rIL-15 from Days 22 to 42 after BCG inoculation inhibited the contraction of effector CD8
ϩ T cells, resulting in an increase of antigen-specific memory CD8 ϩ T cells. However, it could not induce a long-lasting increase and consequently failed to elicit improved efficacy of vaccination against M. tuberculosis as compared with 
